Cargando…
Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland
PURPOSE: Oncology drugs are often approved for multiple indications, for which their clinical benefit varies. Aligning a single price to this differing value remains a challenge. This study examines the clinical and economic value, price, and reimbursement of multi-indication cancer drugs across sev...
Autores principales: | Michaeli, Daniel Tobias, Mills, Mackenzie, Kanavos, Panos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385843/ https://www.ncbi.nlm.nih.gov/pubmed/35821360 http://dx.doi.org/10.1007/s40258-022-00737-w |
Ejemplares similares
-
Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022) -
Healthcare Payer Perspectives on the Assessment and Pricing of Oncology Multi-Indication Products: Evidence from Nine OECD Countries
por: Mills, Mackenzie, et al.
Publicado: (2023) -
Launch sequencing of pharmaceuticals with multiple therapeutic indications: evidence from seven countries
por: Mills, Mackenzie, et al.
Publicado: (2023) -
A New Practical Formulary of Hospitals of England, Scotland, Ireland, France, Germany, &c.
Publicado: (1836) -
Companies’ Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study
por: Wang, Ting, et al.
Publicado: (2020)